CG
BIO icon

Clinton Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Clinton Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,731
Closed -$1.93M – 363
2018
Q1 		$1.93M Sell
7,731
-38,733
-83% -$9.86M 0.21% 153
2017
Q4 		$11.1M Buy
46,464
+36,677
+375% +$8.89M 0.97% 5
2017
Q3 		$2.17M Sell
9,787
-4,668
-32% -$1.05M 0.24% 129
2017
Q2 		$3.27M Buy
14,455
+13,394
+1,262% +$2.92M 0.33% 102
2017
Q1 		$212K Buy
+1,061
New +$204K 0.01% 857
2016
Q3 		– Sell
-6,005
Closed -$859K – 906
2016
Q2 		$859K Buy
+6,005
New +$857K 0.04% 530
2016
Q1 		– Sell
-1,955
Closed -$271K – 864
2015
Q4 		$271K Sell
1,955
-2,151
-52% -$298K 0.02% 658
2015
Q3 		$551K Buy
+4,106
New +$591K 0.05% 420
2015
Q1 		– Sell
-3,460
Closed -$417K – 481
2014
Q4 		$417K Buy
3,460
+1,581
+84% +$182K 0.13% 274
2014
Q3 		$213K Sell
1,879
-318
-14% -$37.7K 0.09% 334
2014
Q2 		$263K Buy
+2,197
New +$268K 0.13% 260

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Clinton Group's BIO Position: Q2 2018 in Review

Clinton Group sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2018, closing a stake of 7,731 shares — an estimated $1.93M sold.

Clinton Group first reported a position in BIO in Q2 2014 and held it in 11 quarters. The position peaked at $11.1M in Q4 2017. 326 funds tracked by Wall St. Rank hold BIO as of Q2 2018.

  • Clinton Group reported no remaining Bio-Rad Laboratories Class A position as of Q2 2018 after selling out during the quarter.
  • Clinton Group sold 7,731 Bio-Rad Laboratories Class A shares in Q2 2018, an estimated $1.93M.
  • Clinton Group first reported a position in Bio-Rad Laboratories Class A in Q2 2014 and held it in 11 quarters.
  • Clinton Group's Bio-Rad Laboratories Class A position peaked at $11.1M in Q4 2017.
  • 326 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2018.

Based on Clinton Group's 13F filing for Q2 2018, filed 6 Jul 2018.